Cheng Chi Wang
Director Técnico/Científico/I+D en LIN BIOSCIENCE, INC. .
Cargos activos de Cheng Chi Wang
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
LIN BIOSCIENCE, INC. | Director Técnico/Científico/I+D | 01/06/2016 | - |
Belite Bio LLC
Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | Director de Operaciones | 01/01/2016 | - |
Fundador | 01/01/2016 | - |
Historial de carrera de Cheng Chi Wang
Formación de Cheng Chi Wang.
University of California San Diego | Masters Business Admin |
National Taiwan University | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 3 |
Taiwán | 3 |
Operativa
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Masters Business Admin | 1 |
Sectorial
Consumer Services | 3 |
Health Technology | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
LIN BIOSCIENCE, INC. | Health Technology |
Empresas privadas | 1 |
---|---|
Belite Bio LLC
Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | Health Technology |
- Bolsa de valores
- Insiders
- Cheng Chi Wang
- Experiencia